Allstate
ALL
$249.83
-0.94%
The Allstate Corporation is one of the largest U.S. property-casualty insurers, with personal auto representing its largest revenue line, complemented by homeowners and other insurance products distributed primarily through roughly 6,000 exclusive agents across North America. As a scaled incumbent in a consolidating P&C market, Allstate competes on brand strength, distribution density, and underwriting discipline against peers such as Progressive, Berkshire Hathaway's GEICO, and Travelers, while its Protection Services segment (reported at $915 million) reflects ongoing diversification beyond core auto and home. The current investor narrative centers on a powerful earnings recovery driven by sharply lower catastrophe losses and sustained policy growth, which has transformed the company from a 2023 underwriting-loss story into a margin-expansion and capital-return story. This turnaround has been amplified by a higher-for-longer interest rate backdrop that boosts investment yields on Allstate's float, though debate persists over how much of the earnings surge is cyclical (benign weather, hard pricing) versus structural, and whether the stock's re-rating has already discounted the recovery.…
ALL
Allstate
$249.83
Related headlines
Investment Opinion: Should I buy ALL Today?
The synthesized recommendation is Hold. The core thesis is that Allstate has executed a remarkable earnings recovery, but the stock's 21.5% one-year gain and 22.6% YTD rise have already priced in much of the good news, leaving limited margin of safety at the current price of $249.83. The analyst consensus rating of Hold (mean 2.6) and average target price of $274.64 imply only 9.9% upside, which is not compelling enough to justify a Buy rating given the cyclical risks.
The supporting evidence for a Hold is balanced. On the positive side, the forward P/E of 9.05x is undemanding, the PEG ratio of 0.043 suggests undervaluation relative to growth, and the dividend yield of 2.12% with a payout ratio of 11.2% is sustainable. Free cash flow of $11.53 billion and debt-to-equity of 0.245 reflect a strong balance sheet. However, revenue growth of 4.17% is modest, and the earnings recovery is largely due to benign weather, which is not a durable competitive advantage. The stock's beta of 0.15 offers defensive characteristics, but the 3.82% one-month decline and underperformance versus the S&P 500 suggest momentum has faded.
The biggest risks that could invalidate the Hold thesis are a severe hurricane season, increased competitive pressure from Progressive, and a decline in interest rates that reduces investment income. The rating would upgrade to Buy if the stock pulls back to the $220-230 range (implying a forward P/E below 9x) or if the company demonstrates sustained underwriting margin expansion through a normal catastrophe year. It would downgrade to Sell if catastrophe losses spike and push the combined ratio above 100%, or if revenue growth turns negative. Relative to its history and peers, the stock appears fairly valued: the forward P/E of 9.05x is in line with historical averages for P&C insurers, and the price-to-book of 1.78x is reasonable. The stock is not overvalued, but it is not a screaming bargain either.
Sign up to view all
ALL 12-Month Price Forecast
Allstate presents a classic cyclical recovery story that is largely priced in. The earnings inflection is impressive, but the stock's 21.5% one-year gain and 22.6% YTD rise have already captured much of the upside. The forward P/E of 9.05x is undemanding, but it is appropriate given the inherent volatility of catastrophe-exposed earnings. The analyst consensus of Hold and average target of $274.64 suggest limited near-term upside. I would upgrade to bullish if the stock pulls back to the $220-230 range or if the company demonstrates sustained margin expansion through a normal catastrophe year. I would downgrade to bearish if catastrophe losses spike or if competitive pressures lead to policy attrition.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $274.77 and implied upside of +10.0% versus the current price.
Average Target
$274.77
0 analysts
Implied Upside
+10.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$191 - $334
Analyst target range
Bulls vs Bears: ALL Investment Factors
The bull case rests on a powerful, data-confirmed earnings recovery: Q1 2026 EPS of $9.36 versus $2.14 a year ago, a forward P/E of just 9.05x, and a fortress balance sheet with $11.53 billion in free cash flow. The bear case centers on the cyclicality of that recovery—benign weather and hard pricing drove the surge, and both could reverse—plus a Hold consensus and stalling price momentum. Currently, the bull evidence is stronger on fundamentals: the earnings inflection is real, the balance sheet is conservative, and the valuation is undemanding. The single most important tension is whether the earnings recovery is structural or merely cyclical; if Allstate can sustain underwriting margins through a normal catastrophe year, the stock is significantly undervalued, but if weather normalizes upward, the forward P/E of 9x could prove to be a value trap.
Bullish
- Earnings inflection is dramatic: Q1 2026 EPS of $9.36 versus $2.14 in Q1 2025 represents a 337% year-over-year increase, driven by catastrophe losses normalizing and pricing actions earning through. Net income of $2.458 billion in Q1 2026 compares to just $595 million a year earlier, confirming the recovery is real and not just base-effect optics.
- Deep value on forward earnings: The stock trades at a forward P/E of just 9.05x based on estimated EPS of $26.30, and a trailing P/E of 5.38x. With a PEG ratio of 0.043, the market is pricing in almost no growth despite the company's earnings recovery and 4.17% revenue growth.
- Analyst targets imply upside: The average analyst target price of $274.64 implies 9.9% upside from the current price of $249.83, with a high target of $334.00 representing 33.7% upside. Even the low target of $191.00 is only 23.5% below current levels, suggesting limited downside relative to the upside skew.
- Fortress balance sheet and cash generation: Debt-to-equity is a conservative 0.245, and free cash flow TTM is $11.53 billion. The dividend yield of 2.12% is well covered with a payout ratio of just 11.2%, leaving ample room for continued capital return and buybacks.
Bearish
- Catastrophe risk is structural: The entire earnings recovery hinges on benign weather. Q1 2025's $2.14 EPS was crushed by elevated catastrophe losses, and a single active hurricane season could rapidly reverse the margin expansion. The 52-week range of $188.08 to $277.22 reflects this volatility.
- Analyst consensus is only Hold: Despite the earnings surge, the recommendation mean is 2.6 (Hold) with 22 analysts covering the stock. This suggests the sell-side views the recovery as largely priced in and sees limited near-term catalysts beyond current levels.
- Momentum has stalled: The stock is down 3.82% over the past month and has underperformed the S&P 500 by 2.86 percentage points. After a strong run from $188 to $277, the stock has been range-bound between $250 and $265 since July 2026, indicating waning momentum.
- Valuation re-rating may be complete: The stock trades at a price-to-book of 1.78x and price-to-sales of 0.82x, which is not cheap for a P&C insurer with cyclical earnings. The forward P/E of 9.05x assumes the $26.30 EPS estimate is sustainable, but if catastrophe losses normalize upward, earnings could disappoint.
ALL Technical Analysis
Beta
0.15
0.15x market volatility
Max Drawdown
-11.5%
Largest decline past year
52-Week Range
$188-$277
Price range past year
Annual Return
+21.5%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | -0.5% |
| 3m | +13.0% | +2.3% |
| 6m | +21.5% | +16.6% |
| 1y | +21.5% | +14.8% |
| ytd | +22.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Quarterly Revenue
$16.9B
2026-03
Revenue YoY Growth
+4.2%
YoY Comparison
Gross Margin
45.3%
Latest Quarter
Free Cash Flow
$11.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
PE
5.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sustainability of Allstate's earnings recovery. Q1 2026 net income of $2.458 billion was driven by a 45.3% gross margin, but this compares to a 18.6% gross margin in Q1 2025 when catastrophe losses were elevated. The company's current ratio of 0.37 is low, though typical for insurers, and its $11.53 billion free cash flow TTM provides a cushion. However, the 337% EPS growth is unlikely to repeat, and any normalization of catastrophe losses could pressure margins. Additionally, Allstate's revenue growth of 4.17% is modest, and its reliance on personal auto—its largest revenue line—exposes it to pricing competition and regulatory rate approvals.
Market and competitive risks include valuation compression if the earnings recovery stalls. The stock trades at a forward P/E of 9.05x, which is low relative to the S&P 500 but may be appropriate given the cyclicality of insurance earnings. The beta of 0.15 indicates low market correlation, but sector rotation away from financials could pressure the stock. Recent news highlights that higher interest rates benefit insurers through better investment yields, but if rates decline, that tailwind fades. Competitive threats from Progressive and GEICO, which have gained market share through direct distribution and telematics, could limit Allstate's growth. The analyst consensus of Hold (mean 2.6) suggests limited near-term upside, and the stock's 3.82% decline over the past month indicates waning momentum.
The worst-case scenario would be a combination of a severe hurricane season, increased auto competition, and a decline in interest rates. This could cause earnings to revert toward 2025 levels, where Q1 EPS was $2.14. In such a scenario, the stock could retest its 52-week low of $188.08, representing a 24.7% decline from the current price of $249.83. The analyst low target of $191.00 implies a 23.5% downside. A more extreme scenario, such as a catastrophic hurricane season causing $5+ billion in losses, could push the stock below $180, a 28% decline. Investors should be aware that the stock's max drawdown over the past 180 days was -11.48%, but a true catastrophe year could cause a larger drawdown.
FAQ
The most severe risk is catastrophe exposure: a single active hurricane season could cause billions in losses and reverse the earnings recovery, potentially pushing the stock toward its 52-week low of $188.08. Second, competitive pressure from Progressive and GEICO could lead to policy attrition and slower revenue growth, which is already modest at 4.17%. Third, interest rate risk: if the Fed cuts rates, investment income could decline, reducing a key tailwind. Fourth, regulatory risk: rate increase denials in key states could pressure margins. Finally, valuation risk: the stock's 21.5% one-year gain means much of the good news is priced in, and any earnings miss could trigger a sharp sell-off.
Our 12-month forecast has three scenarios. The base case (55% probability) targets $260-285, assuming a normal catastrophe year and EPS of $26.30. The bull case (25% probability) targets $300-334, driven by another benign weather year and multiple expansion. The bear case (20% probability) targets $188-210, triggered by a severe hurricane season and competitive pressures. The most likely scenario is the base case, which implies a total return of 4-14% including dividends. The key assumption is that catastrophe losses remain within historical averages; any deviation could significantly alter the outcome.
ALL appears fairly valued to slightly undervalued on forward earnings, but the valuation is not a screaming bargain. The forward P/E of 9.05x is below the S&P 500 average, but it is in line with historical averages for P&C insurers. The price-to-book ratio of 1.78x is reasonable, and the PEG ratio of 0.043 suggests the stock is cheap relative to its growth rate. However, the trailing P/E of 5.38x is distorted by the cyclical earnings recovery. The market is pricing in a sustainable earnings level of around $26.30 per share, which assumes normal catastrophe losses. If that assumption holds, the stock is undervalued; if not, it is fairly valued or even overvalued.
At the current price of $249.83, ALL is a Hold rather than a strong Buy. The stock has already rallied 21.5% over the past year and 22.6% YTD, and the average analyst target of $274.64 implies only 9.9% upside. The forward P/E of 9.05x is attractive, but it reflects the cyclicality of insurance earnings. The biggest downside risk is a severe hurricane season, which could push the stock back toward its 52-week low of $188.08, a 24.7% decline. For long-term investors seeking a low-beta dividend payer, ALL is a reasonable holding, but new money may find better entry points on a pullback to the $220-230 range.
ALL is best suited for long-term investors seeking a low-beta, dividend-paying value stock with cyclical upside. The beta of 0.15 means it is not a volatile trading vehicle, and the 2.12% dividend yield with a low payout ratio of 11.2% provides steady income. Short-term traders may find limited opportunities given the stock's recent range-bound trading between $250 and $265. A minimum holding period of 2-3 years is recommended to ride out the insurance cycle and benefit from compounding dividends and potential multiple expansion. The stock is not appropriate for those seeking high-growth or momentum exposure.